医药生物行业周报：多家医药公司3月纳入港股通，交易流动性有望提升-20260309

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The pharmaceutical sector has underperformed compared to the broader market, with a decline of 2.78% over the past week, while the Shanghai Composite Index fell by 1.07% [10]. - The report highlights that 42 companies will be included in the Hong Kong Stock Connect on March 9, 2026, with 13 from the biopharmaceutical and healthcare sectors, which is expected to enhance trading liquidity and shareholder structure [4][11]. - The current valuation of the pharmaceutical sector is 33.3 times PE based on 2026 earnings forecasts, representing a 26% premium over the overall A-share market (excluding financials) [4][11]. Summary by Sections 1. Industry Performance - The pharmaceutical sector ranks 17th among 31 primary sub-industries, with specific sub-sectors like medical services and biological products experiencing significant declines [10]. - Year-to-date, the pharmaceutical sector has yielded a return of 0.10%, lagging behind the Shanghai Composite Index's return of 0.66% [4][10]. 2. Market Dynamics - The report notes that the pharmaceutical sector's performance has been affected by various factors, including recent policy adjustments and market sentiment [4][10]. - The report emphasizes the ongoing innovation in domestic pharmaceutical companies, which is expected to drive future growth [4]. 3. Valuation Metrics - The TTM (Trailing Twelve Months) PE ratio for the pharmaceutical sector is currently at 30.5, which is below the historical average of 34.9 [4][11]. - The report indicates that the pharmaceutical sector's valuation is relatively attractive compared to the overall market, suggesting potential investment opportunities [4][11]. 4. Key Companies to Watch - The report identifies several companies to focus on, including Aidi Pharmaceutical, WuXi Biologics, and others, which are expected to benefit from the current market dynamics [4][5].